Market News & Trends
Roivant and Pfizer Unveil Priovant Therapeutics & Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Roivant Sciences and Pfizer recently announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity…
Terumo Blood and Cell Technologies & GenCure Collaborate to Advance Cell & Gene Therapy Manufacturing Solutions
Terumo Blood and Cell Technologies recently announced it has signed a new collaborative agreement with GenCure, a subsidiary of BioBridge Global, to extend and unify cell and gene therapy manufacturing solutions…..
Fate Therapeutics Announces Expansion of Solid Tumor Collaboration With ONO Pharmaceutical
Fate Therapeutics, Inc. recently announced it has expanded its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy collaboration with ONO Pharmaceutical Co., Ltd. to include the development of….
WuXi STA Opens A High-Potency API Plant
WuXi STA, a WuXi AppTec company, has recently opened another high-potency API (HPAPI) plant at its Changzhou site (Jiangsu, China). The new plant will meet…
Verrica Pharmaceuticals Holds Type A Meeting With FDA for VP-102 for Molluscum Contagiosum
Verrica Pharmaceuticals Inc. recently announced the company held a Type A meeting with the US FDA on June 27, 2022, regarding the path forward for…
Akoya Biosciences to Partner With Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature Test Into a Companion Diagnostic
Akoya Biosciences, Inc. and Acrivon Therapeutics, Inc. recently announced an agreement to co-develop, validate, and commercialize Acrivon’s OncoSignature test, a first-of-its-kind companion diagnostic. The test will…
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
Soligenix, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for a Phase 2a clinical trial titled Phase 2 Study…
Vetter’s Newest Clinical Manufacturing Site Successfully Completed its First Customer Fills
With the realization of the first successful customer fills, Vetter has reached another milestone at its new clinical manufacturing facility in Rankweil, Austria. Further batches are already planned,….
Artelo Biosciences Presents Positive Pre-Clinical Results for Novel FABP5 Inhibitor
Artelo Biosciences, Inc. recently announced Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences, presented new research results titled Discovery and Preclinical Evaluation…
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer
Evaxion Biotech A/S recently announced it has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned…
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
Diffusion Pharmaceuticals Inc. recently announced positive effects from its second Oxygenation Trial, the Altitude Trial. “This was a specialized study designed to evaluate TSC’s novel oxygen-enhancing mechanism…
Cullinan Oncology & Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop & Commercialize CLN-081/TAS6417
Cullinan Oncology, Inc. recently announced the completion of its agreement with Taiho Pharmaceutical Co., Ltd. (Taiho) signed in May 2022. Per the terms of the agreement….
Silo Pharma Expands License Agreement & Patent Portfolio
Silo Pharma, Inc. recently announced that it has expanded its Commercial Evaluation License Agreement (CELA) with the University of Maryland Baltimore (UMB) for its next generation Liposomal Peptide targeting….
SCYNEXIS Announces Initiation of New Phase 3b Study to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis
SCYNEXIS, Inc. recently announced the initiation and first patient enrolled in a new Phase 3b, open-label, multicenter study (VANQUISH) to evaluate the efficacy, safety and tolerability…
Apellis Expands R&D Collaboration With Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain
Apellis Pharmaceuticals, Inc. and Affilogic recently announced the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins….
Precision BioSciences Announces In Vivo Gene Editing Collaboration With Novartis
Precision BioSciences, Inc. recently announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma….
Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC
Pasithea Therapeutics Corp. recently announced its acquisition of Alpha-5 integrin, LLC, a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of amyotrophic lateral sclerosis (ALS) and….
Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial & Urothelial Cancer Patients
Acrivon Therapeutics, Inc. recently announced the US FDA has cleared the company's Investigational New Drug (IND) application for its lead asset ACR-368 in a Phase…
USPTO Issues Patent Covering Use of XPro for Treatment of CNS Diseases
INmune Bio, Inc. recently announced the issuance of US Pat. No. 11,365,229 for METHODS OF TREATING NEUROLOGICAL DISEASES, a patent directed to use of Dominant…
Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial
Biomea Fusion, Inc. recently announced the first patient has been dosed in the MM cohort of COVALENT-101, the company’s Phase 1 clinical trial evaluating BMF-219,…
